Real-world study of overall survival ... - SHARE Metastatic ...

SHARE Metastatic Breast Cancer

6,809 members8,426 posts

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer

Hazelgreen profile image
9 Replies

npj Breast Cancer volume 8, Article number: 114 (2022)

The Flatiron Health Analytic Database was used to assess overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) metastatic breast cancer (MBC) treated with first-line palbociclib plus an aromatase inhibitor (AI) versus an AI alone in routine US clinical practice. In total, 2888 patients initiated treatment during February 3, 2015–March 31, 2020, with a potential ≥6-month follow-up (cutoff date, September 30, 2020). After stabilized inverse probability treatment weighting, median OS (95% CI) is significantly longer among palbociclib versus AI recipients (49.1 [45.2–57.7] versus 43.2 [37.6–48.0] months; hazard ratio, 0.76 [95% CI, 0.65–0.87]; P < 0.0001). Progression-free survival (95% CI) is 19.3 (17.5–20.7) versus 13.9 (12.5–15.2) months, respectively (hazard ratio, 0.70 [95% CI, 0.62–0.78]; P < 0.0001). These data support first-line palbociclib plus an AI treatment for HR+/HER2− MBC.

Written by
Hazelgreen profile image
Hazelgreen
To view profiles and participate in discussions please or .
Read more about...
9 Replies
Susan1953 profile image
Susan1953

Thanks for sharing. 5 years 7 months for me.

Merma profile image
Merma

Good to know…5 yrs for me.

TE53_67 profile image
TE53_67

thanks for the upload of this data. Do I read it right that the longest overall survival was 57 months for those on Pal. Albeit I see on this platform lots of ladies on this and longer. Sorry I may be reading this incorrectly.

Hazelgreen profile image
Hazelgreen in reply toTE53_67

Hello,

The range around the median (49.1 mos) for those on Pal is indeed 45.2 to 57.7mos. That range gives the 95% probability that the true median falls within that range. Statisticians always consider the fact that they are sampling data from a limited number of patients so need to consider whether their sample could be biased. As patients, we don't have to care about the range around the median. Instead, what we need to know is that 50% of the patients taking Pal lived at least 49 months (and were continuing to live now that the study was over). It would take a much longer follow-up study to determine which patient lived the longest.

Please let me know if my explanation doesn't make this clearer.

Regards,

Cindy

TE53_67 profile image
TE53_67 in reply toHazelgreen

hi Cindy this completely makes sense. A light bulb moment, of course this is the end of the study and not the patients life as they are still under treatment currently! Thank you so much for explaining it further. All good feedback overall then.

diamags profile image
diamags

To all our friends out there, remember these are statistics and although we make up statistics, individually we're not. I have been on AIs alone for 9 years with no progression!!!

Hazelgreen profile image
Hazelgreen

Aww, diamags, that's terrific to read! Thanks for sharing. It is clear that the median for the AI control group is also only talking about those at the 50th percentile. In this study, half the AI only group were still alive after 43 months of treatment.

Hugs, Cindy

Guitarbella profile image
Guitarbella

Dear Hazelgreen, thank you as always for sharing this encouraging information. I am a bit confused about overall survival and PFs. For example I had 21 months PFS on Palbo & Letrazole, so has this now meant I could have a longer chance of median Overall Survival of 49.1 months as opposed to the 3 years from previous statistics,

Or am I getting ahead of myself?

Many thanks for your help with this.

I hope you are doing well?

Guitarbella

Hazelgreen profile image
Hazelgreen in reply toGuitarbella

Hi Bev,

I looked at your earlier posts, and understand that you are now on Paclitaxel for liver mets. I hope that will restore your liver enzymes to their normal ranges.

Since you had progression when you were taking palbociclib and letrozole, this suggests that this combo did not work as well for you as it did for the majority of the patients in the study I mentioned above. If you were just starting the combo now, the best guess would be that you would get at least 49.1 months from it. However, in your case, we know how long it worked for you (21 months) so no one needs to guess. I do not think your oncologist will want you to take this same combo in the future.

I'm in Canada which also has socialized medicine so I don't have to pay for the ribociclib I am taking for my extensive mets. I am very grateful for our system! My oncologist has already mentioned that patients are only given one of these very expensive CDK4/6 inhibitors most of us on this site are taking. (Even with the Canadian government's negotiating, these CDK4/6 inhibitors cost over $6600 per month per patient!)

Thanks for asking about my health. I soon will have been taking ribociclib (Kisqali) for a year. My cancer markers have shrunk from 125 to 38 so it seems to be working so far. I continue to have extensive mets (bones, lungs, liver, lymph system, spleen, skin, etc.) but I feel lucky that, at my age (77 yrs.), the mets tend to be slow-growing so have not reached my brain, and my liver enzymes continue to be in the normal range.

From my liver biopsy, my oncologist knows that I have the PIK3CA mutation so has said that I will be switched to Piqray once Kisqali quits working. I have found the side effects from Kisqali bad enough that I certainly am not looking forward to the side effects from Piqray! I may choose to take nothing if it comes down to that.

Hugs, Cindy

Not what you're looking for?

You may also like...

Overall Survival With Palbociclib and Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer

Published in Oncology and Journal Scan / Research · September 06, 2022 This updated exploratory...
Hazelgreen profile image

HER2-low status may not affect survival outcomes of patients with MBC receiving palbociclib plus ET as frontline therapy.

A retrospective study was conducted with "252 consecutive HR+/HER2- MBC patients who...
Hazelgreen profile image

Trastuzumab Deruxtecan Extends Survival Over Chemotherapy for Patients With HER2-Positive Metastatic Breast Cancer

Trastuzumab deruxtecan (T-DXd) was associated with higher response rates and longer survival than...
Hazelgreen profile image

Palbociclib and Overall Survival

Published in Metastatic Breast Cancer and Journal Scan / Research · June 30, 2022 Overall Survival...
Hazelgreen profile image